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Abstract
Background: Up to 60% of patients with bipolar disorder (BD) have a history of traumatic events, which is associated
with greater episode severity, higher risk of comorbidity and higher relapse rates. Trauma-focused treatment strategies
for BD are thus necessary but studies are currently scarce. The aim of this study is to examine whether Eye Movement
Desensitization and Reprocessing (EMDR) therapy focusing on adherence, insight, de-idealisation of manic symptoms,
prodromal symptoms and mood stabilization can reduce episode severity and relapse rates and increase cognitive
performance and functioning in patients with BD.
Methods/design: This is a single-blind, randomized controlled, multicentre trial in which 82 patients with BD and a history of
traumatic events will be recruited and randomly allocated to one of two treatment arms: EMDR therapy or supportive therapy.
Patients in both groups will receive 20 psychotherapeutic sessions, 60 min each, during 6 months. The primary outcome is a
reduction of affective episodes after 12 and 24 months in favour of the EMDR group. As secondary outcome we postulate a
greater reduction in affective symptoms in the EMDR group (as measured by the Bipolar Depression Rating Scale, the Young
Mania Rating Scale and the Clinical Global Impression Scale modified for BD), and a better performance in cognitive state,
social cognition and functioning (as measured by the Screen for Cognitive Impairment in Psychiatry, The Mayer-Salovey-
Caruso Emotional Intelligence Test and the Functioning Assessment Short Test, respectively). Traumatic events will be
evaluated by The Holmes-Rahe Life Stress Inventory, the Clinician-administered PTSD Scale and the Impact of Event Scale.
Discussion: The results of this study will provide evidence whether a specific EMDR protocol for patients with BD is effective
in reducing affective episodes, affective symptoms and functional, cognitive and trauma symptoms.
Trial registration: The trial is registered at ClinicalTrials.gov, identifier: NCT02634372. Registered on 3 December 2015.
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Background
Bipolar disorder (BD) is a serious neuropsychiatric condi-
tion of major public health importance with a complex
multifactorial etiology, involving both genetic and environ-
mental factors and associated with high mortality by sui-
cide. BD is characterized by chronic instability of mood,
circadian rhythm disturbances and continual fluctuations in
energy levels, affect, sleep and cognitive appraisal of the self
and others [1]. Although the disorder is conventionally
characterized as being episodic in nature, with full recovery
between periods of mania and depression, recent data sug-
gest that many bipolar patients do not obtain a complete
remission but continue to experience subsyndromal manic
or depressive symptoms [2]. This is a clinically important
issue since (1) subsyndromal symptoms are associated with
a higher risk of relapses and poorer social functioning [3]
and (2) interepisode affective instability seems to be refrac-
tory to pharmacological treatment [4]. Further possible risk
factors for relapses include substance abuse, comorbid anx-
iety disorders, personality disorders or physical diseases [5].
The intervention strategies available for BD include es-
sentially pharmacotherapy but also, increasingly, psycho-
social interventions such as cognitive behavioral therapy,
psychoeducation, interpersonal and social rhythm therapy,
and family intervention [6]. However, despite the everyday
use in clinical practice of both types of intervention,
almost 70% of BD patients suffer from at least one
affective relapse within 2 to 4 years [7–9].
The comorbidity of posttraumatic stress disorder (PTSD)
with BD, with a prevalence of 16 to 39% of bipolar patients
[10], might hereby have an important clinical implication.
Traumatized bipolar patients suffer from more rapid cycling,
more suicide attempts, more substance abuse, have a lower
quality of life and more (hypo)manic and depressive symp-
toms than bipolar patients without PTSD [11, 12]. It is also
of concern that early childhood adverse events, not necessar-
ily fulfilling PTDS criteria, can trigger severe mental disor-
ders – such as BD – later in life, with a negative impact on
the course of the illness (e.g., [13]). Also, it is well established
that adverse life events that occur later in life can negatively
affect the course of the disease and can be important
contributors to a poorer outcome (e.g., [14]). Studies hereby
provide evidence that patients with severe mental illness and
traumatic life events show more psychiatric symptoms, in-
creased risk of suicide, increased frequency of risky sexual
behaviors, more admissions to psychiatric hospitals and,
overall, a greater risk of being re-traumatized [15, 16]. A
recent naturalistic study over 4 years found an increase of
depressive episodes in BD when patients were experiencing
life events 6 months prior to the affective index episode [17].
However, this diagnostic comorbidity with significant
negative effects on the prognosis of BD has been until
recently largely ignored with an intriguing lack of trials for
traumatized bipolar patients.
One form of treatment that is being increasingly used in
PTSD is Eye Movement Desensitization and Reprocessing
(EMDR) [18]. This integrative psychotherapeutic approach
uses standardized protocols and elements of cognitive
behavioral, interpersonal, and body-centered therapies in
conjunction with dual stimulation (e.g., horizontal eye
movements from side to side) [18, 19]. The results of two
independent meta-analyses and reviews have shown that
EMDR therapy is as effective in the treatment of PTSD
symptoms as cognitive behavioral therapy [20–22]. The
treatment with EMDR has also recently shown a beneficial
and comparable effect to exposure therapy on patients
with psychosis and comorbid PTSD in a large randomized
controlled trial (RCT) [23]. Our group carried out the first
pilot RCT of EMDR in bipolar patients with a history of
traumatic events and subsyndromal symptomatology.
Results showed that the EMDR intervention not only
reduced the symptoms associated with trauma in the
patients, but also had beneficial effects on subsyndromal
affective symptoms [24]. Following these promising re-
sults, our research group has developed a specific and
comprehensive EMDR protocol for bipolar patients with a
history of trauma [25]. This protocol consists of a detailed
survey of traumatic events, the intervention and process-
ing of these events according to the Shapiro standard
protocol [19] and five subprotocols directed to (1) mood
stabilization, (2) enhancement of treatment adherence, (3)
increase insight, (4) treatment of prodromal symptoms
and (5) de-idealization of manic symptoms.
We hypothesized that our EMDR Bipolar protocol, as
an adjunct to pharmacological treatment would have
beneficial effects on the course of the illness of bipolar
patients with a history of traumatic events.
Methods/design
This multicenter collaborative project will involve the par-
ticipation of three different centers from the Barcelona
catchment area, Spain (Hospital Benito Menni, Hospital
Clinic of Barcelona and Hospital del Mar). EMDR and
supportive therapy (ST) therapists have extensive experi-
ence in the application of both psychotherapies. EMDR
therapists have already participated in the pilot study [24]
and all therapists received a detailed day training in apply-
ing the EMDR therapy protocol and a well-defined ST
program. The application of all clinical assessments has
been defined and practiced within all participating raters.
All centers and research groups involved have wide ambu-
latory facilities and outpatient clinics for BD patients that
will facilitate meeting the recruitment criteria and devel-
opment of this project.
Study aim
The overall aim of this study is to examine whether the
EMDR Bipolar protocol for BP with a history of traumatic
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events can reduce affective relapses, improve affective and
trauma-related symptoms and result in a better perform-
ance in cognition and psychosocial functioning, when
compared ST. Other related aims of this trial are to ex-
pand the available options for psychosocial intervention in
BD, to explore that the EMDR therapy is a safe and effect-
ive tool in traumatized bipolar patients and that treatment
with EMDR leads to an improvement in the course and
prognosis of the disease.
Based on our pilot study of EMDR in traumatized
bipolar patients, we propose the following hypotheses:
1. The EMDR group will show fewer affective relapses at
12 and 24 months’ follow-up compared to the ST group
2. Patients in the EMDR group will show fewer
affective and trauma-related symptoms compared to
the ST group at evaluations after 6 months of
therapy, at 12 and 24 months
3. Patients in the EMDR group will show a better
cognitive and psychosocial functioning compared to
the ST group at evaluations after 6 months of
therapy, at 12 and 24 months
Trial design
This is a single-blind, randomized controlled clinical
trial with two parallel branches, EMDR and ST. Patients
will be matched for age, sex, illness duration and num-
ber of affective episodes the year before the clinical trial.
The primary outcome variables that are affective re-
lapses, symptoms of trauma and cognition and psycho-
social functioning, will be assessed at six time points;
pretreatment (T0), mid-treatment at 2 weeks (T1) and at
3 months (T2), post treatment at 6 months (T3), and
follow-up evaluations at 12 (T4) and 24 months (T5)
(see Fig. 1). The secondary outcome variables that are
the course and prognosis of the disease, will be assessed
in follow-up evaluations at 12 (T4) and 24 months (T5).
The research assistants conducting the clinical assess-
ments will be blind to the participants’ research condi-
tion. Patients are not blind to treatment as it is
impossible for a therapist to offer and for a patient to re-
ceive therapy without being aware of the techniques that
they are using orreceiving. The study has been approved
by the Ethics Committee of the Germanes Hospitalàries
del Sagrat Cor de Jesús (reference number: PR-2014-15),
the Hospital Clínic of Barcelona (reference number:
HCB/2015/1005) and the Hospital del Mar (reference
number: 2015/6502/l). All participants will sign in-
formed consent prior to enrollment. Details of the trial
design can be also gathered from Additional file 1
(Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) flow diagram) and the SPIRIT
Checklist (Additional file 2).
Participants
The patient sample will consist of 82 patients fulfilling
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition, text revision (DSM-IV-TR) criteria for bi-
polar I and II disorder, based on clinical interview and
review of case notes. Inclusion criteria will be: (1) age
between 18 and 65 years, (2) presence of between two
and six affective episodes in the last year, (3) current
clinical status of euthymia upon clinical evaluation, de-
fined as the presence of clinical remission (Bipolar De-
pression Rating Scale (BDRS) <8 and Young Mania
Rating Scale (YMRS) <6; or subsyndromal status defined
as BDRS ≥8 and <14 and/or YMRS ≥7 and <12), (4)
presence of one or more traumatic events causing
current trauma-related symptoms (The Holmes-Rahe
Life Stress Inventory, H-RLSI >0; The Clinician-
administered PTSD Scale (CAPS): frequency event >1,
intensity of symptom >2; Impact of Event Scale-Revised,
IES-R >0), and – following the standard EMDR protocol
[19] – Subjective Units of Distress (SUD) >5 (range from
0 to 10, with a score of 10 meaning maximum stress).
Exclusion criteria will be: (1) substance abuse/depend-
ency within 3 months prior to participation (except of
nicotine abuse/dependency), (2) neurological disease or
brain trauma history, (3) suicidal ideation, (4) previous
involvement in trauma-focused therapy, (5) current psy-
chotherapy during the study and months of follow-up.
Randomization procedure
All patients meeting the inclusion criteria receive the pre-
treatment (T0) assessment. After T0, participants will be
assigned to EMDR or the ST group by two independent re-
searchers using the following covariate-adaptive allocation
procedure [26]: (1) the first two patients will be randomly
allocated to EMDR or ST with p = 0.5, (2) the next patients
will be allocated as follows: (b1) if one group already in-
cludes two more patients than the other group, the patient
will be randomly allocate to EMDR or ST with p = 0.8 for
the smallest group and p = 0.2 for the largest group, (b2)
otherwise, we will first simulate that the patient is allocated
to EMDR and calculate the sum of the between-group
square standardized differences in age, sex, illness duration
and number of affective episodes the year before the clinical
trial between groups, we will then simulate that the patient
is allocated to ST and recalculate the sum, and finally ran-
domly allocate the patient to EMDR or ST with p = 0.8 for
the group with the smallest sum and p = 0.2 for the group
with the largest sum. For example, if we had already in-
cluded 10 patients to the EMDR group and 8 patients to
the ST group, the 19th patient would be randomly allocated
with p = 0.2 for EMDR and p = 0.8 for ST. If they were allo-
cated to ST, we would calculate the above sum of covariates
after simulating that the 20th patient is allocated to EMDR
and after simulating that is allocated to ST, and if the sum
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of the EMDR simulation was larger than the sum of the ST
simulation, we would randomly allocate the 20th patient
with p = 0.2 for EMDR and p = 0.8 for ST. Following this
procedure, final groups should be balanced in size and
matched in age, sex, duration and episodes. All steps of the
randomization process will be automatically carried out in
a central location using a computer program.
Computation of sample size
The main aim of the study is to assess the relative efficacy
of a specific EMDR intervention protocol versus ST
therapy in the clinical stabilization (decrease in the risk of
relapse) of traumatized bipolar patients. For this reason the
reduction of the risk of relapse after treatment with a
follow-up of 24 months will be used as the dependent
variable of the study. The calculation of the sample size was
based on a survival analysis using the statistical package
“powerSurvEpi” for R (http://www.r-project.org/) using an
alpha = 0.005 instead of 0.05 to allow correction for
multiple comparisons. The number of patients required to
detect a hazard ratio = 2 (i.e., the hazard rate of relapse is
one group is the double of the hazard rate in the other
group) in a Cox regression with a statistical power of 80%
and alpha = 0.005 is n = 36 per intervention group (two
groups, EMDR and ST, equals to a total n = 72). According
to Chambless and Hollon (1998) a sample of this size
should show clinically relevant differences [27]. Assuming a
percentage of dropouts of about 10–15% of the participants
it would be necessary to recruit approximately 82 patients,
41 allocated in each intervention arm.
Fig. 1 Flow diagram of enrollment, intervention and assessments. YMRS: Young Mania Rating Scale; BDRS: Bipolar Depression Rating Scale;
CGI-BP-M: Clinical Global Impression, PTSD: Posttraumatic Stress Disorder; CAPS: Clinician Administered PTSD Scale; IES-R: Impact Event Scale; H-RLSI:
The Holmes-Rahe Life Stress Inventory; SUD: Subjective Units of Distress; SCIP: Screen for Cognitive Impairment in Psychiatry; MSCEIT: The Mayer-
Salovey-Caruso Emotional Intelligence Test; FAST:Functioning Assessment Short Test; CLQ-8: Client Satisfaction Questionnaire
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Interventions
Eye Movement Desensitization and Reprocessing (EMDR)
EMDR is a psychotherapeutic approach designed to
alleviate the distress associated with traumatic memories
facilitating the access and process of traumatic memories
and other adverse life experience to bring these to an
adaptive resolution. The EMDR therapy will consist of
20 individual sessions 60 min each over a period of
6 months. As stated before, the EMDR Bipolar protocol
will include an evaluation of the psychiatric history of
the patient and an assessment of dysfunctional cogni-
tions and identification of targets in the context of trau-
matic events. In addition, the reprocessing of traumatic
events will follow the standardized protocol of Shapiro
[19] together with the five subprotocols specific for BD
that target the following areas:
1. Mood stabilization: the major goal in the treatment
process of bipolar patients is the long-term
normalization of mood. The aim of this protocol is
to reinforce the positive experiences of affective sta-
bility and self-control in bipolar patients. Via bilat-
eral stimulations this protocol uses also positive
cognitions to strengthen the adaptive system of be-
liefs. When this installation is reinforced repeatedly,
patients are expected to experience an improvement
in their self-esteem and affective stability that, in
turn, is connected with positive body sensations
2. Treatment adherence: poor adherence in bipolar
patients is mainly caused by the feeling of being
controlled by drugs, (hypo)manic episodes, lack of
insight, a negative view on pharmacological
treatment, substance abuse, lack of treatment
response and side effects such as weight gain and
sedation [27]. This protocol aims to identify and
improve those issues and strengthen adherence to
avoid further affective relapses. First, we find out
what subjective problems are connected to the
psychopharmacological treatment. Then, the
therapist suggests various positive consequences
from taking medication. These are then connected
to positive cognitions, emotions or body sensations,
and installed via bilateral stimulation
3. Illness awareness: the aim is to help clients be more
aware of their disease. Good awareness is associated
with fewer affective symptoms and risky behavior,
better adherence to treatment, and a healthier
lifestyle. Being aware of BD can help the client to
take medication more reliably, act more consistently
concerning eating and sleeping habits, reduce risky
behaviors, and facilitates asking for professional help
when necessary. In this protocol, the therapist
reviews with the patient which kind of affective
symptoms suggestive of BD experienced the subject
in the past. Then, the therapist proposes positive
beliefs connected to the fact of having experienced
symptoms and being aware of them; this will be
reinforced with bilateral stimulation
4. Detection of prodromal symptoms: the aim of this
protocol is to help bipolar patients to identify early
prodromal symptoms such as sleep disturbances,
mood changes/lability, psychotic symptoms,
agitation, restlessness, increased anxiety and changes
in appetite or suicidal ideas. In this way, patients can
request a rapid therapeutic intervention to avoid an
affective relapse. After the identification of individual
prodromal symptoms, the therapist proposes a list of
positive beliefs connected to the ability to identify
prodromal symptoms. Then, the therapist reinforces
prodromal symptom awareness with positive
cognitions using bilateral stimulation
5. De-idealization of pleasurable manic symptoms: the
aim of this protocol is to assist patients who are aware
of manic episodes but still idealize specific pleasant
euphoric symptoms and ignore the devastating
consequences of these symptoms during a manic
episode, running a higher risk of poor adherence and
further affective relapses. First, the therapist creates
with the patient a list of manic-state life experiences
that ended in disastrous consequences and connect
each experience that occurs during a mixed or manic
state with the corresponding impulse, action,
sensation, belief and thought. Then, the therapist
strengthens via bilateral stimulation the patient’s
awareness connecting manic symptoms and
impulsivity with disastrous consequences
Some EMDR sessions will be recorded on video ran-
domly and will be evaluated by an external expert in EMDR
to verify that the protocol is being administered properly.
Individual supportive therapy (ST)
ST is a psychological treatment that encourages patients to
express and evaluate their life situation. Living with a men-
tal disease can significantly impact all major domains of life
and this can understandably provoke in patients negative
feelings such as frustration, helplessness or depressive
symptoms. ST also consists of 20 individual sessions of
60 min each over a period of 6 months. One of the main
objectives of ST is to offer an opportunity for the subjects
to express how their lives are affected by the illness. The ST
is a patient-centered, active-listening intervention that en-
ables the patient to receive emotional support and counsel-
ling. We also included general advice and information
about BD and medication without referring to written or
structured material. We offer an unstructured training to
enhance assertive behavior; we also include relaxation exer-
cises, problem-solving training and the use of a mood diary
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or specific mobile app as a tool for tracking the warning
signs of a bipolar episode. Single ST was chosen as control
condition because it provides an intervention for the pa-
tient of similar intensity but with no particular focus on the
processing of traumatic events or on structured psychoedu-
cative interventions of the disorder.
Dropouts and follow-up
In case of an affective relapse with admission to the hospital
during the intervention phase of 6 months patients will be
excluded from the trial and considered as dropouts. In case
of relapse which requires an admission to the hospital dur-
ing the follow-up, patients will be maintained in the trial to
obtain maximum information on the course of the illness.
Assessments
Demographical and clinical variables will be collected
through an interview using the medical history of the pa-
tients and a specific Case Report Form (CRF) for the study,
including sex, age, age of onset of the disorder, number of
relapses, number of previous episodes, history and number
of suicide attempts previous and current pharmacological
treatment, family background and consumption of drugs.
To ensure privacy of participants and safe data storage, data
will also be entered in a data file anonymously; participants
will be given a unique number, and only the research assist-
ant will be able to link the number with the name of the
patient. At baseline (T0) research assistants will also assess
clinical severity of affective symptoms, presence of trau-
matic live events and trauma symptoms, and cognitive and
psychosocial functioning. At 2 weeks (T1) and 3 months
(T2) of treatment patients will be evaluated with respect to
clinical symptoms. After the treatment phase (T3) subjects
will be interviewed with respect to clinical symptoms,
trauma scales, cognitive and psychosocial functioning and
patient satisfaction. During two follow-up visits at 1 year
(T4) and 2 years (T5), blind-to-treatment evaluators apply
clinical affective and trauma scales, functioning and cogni-
tion. See Fig. 1 (flow diagram of enrollment, intervention
and assessments).
The clinical severity will be assessed by means of
different instruments (see Table 1):
1. The BDRS [28], Spanish validation (BDRS-S) [29]:
the BDRS is the most up-to-date and appropriate
tool to assess depressive and mixed symptoms in
DSM-IV-diagnosed bipolar I and II patients. The
BDRS comprises 20 items that evaluate the clinical
features associated with the depressive phase of BD,
including atypical symptoms and mixed phenomen-
ology [28]. Symptom severity are rate on a 4-point
scale ranging from 0 = no symptoms present,
1 = mild, 2 = moderate, 3 = severe
2. The YMRS [30], Spanish validation [31], is a
heteroadministered scale composed of 11 items
aimed at quantifying the severity of manic and
hypomanic episodes. There are four items that are
graded on a 0 to 8 scale (irritability, speech, thought
content and disruptive/aggressive behavior), while
the remaining seven items are graded on a 0 to 4
scale. These four items are given twice the weight of
the others to compensate for poor cooperation from
severely ill patients. Strengths of the YMRS include
its brevity, widely accepted use, and ease of
administration
3. The Clinical Global Impression Scale modified for BD
(CGI-BP-M) [32], Spanish validation [33]: the CGI-
BP-M scale consists of three subscales; the first two
assess the severity of acute symptoms of mania and
depression, and the third evaluates the longitudinal
severity of the disease. Each subscale has seven
subcategories with scores from 1 to 7 rating the
severity of the disorder as normal, low, mild,
moderate, marked, severe or very severe
Trauma symptoms will be evaluated using the tools
listed in Table 2:
1. The Clinician-Administered PTSD Scale (CAPS) [34],
Spanish validation [35]: the CAPS is the standard scale
in the evaluation of the presence or absence of PTSD
diagnosis and the frequency and intensity of the
symptoms. This scale provides ratings of the
frequency and intensity of each of the 17 DSM-IV-
TR-based PTSD symptoms on a 0 to 4 Likert-type
scale, thereby allowing for a maximal score of 8 for
each symptom and a total score range from 0 to 136
[23]. It can be used to diagnose a current or past
trauma, or to evaluate symptoms during the last week
2. The Impact of Event Scale Revised (IES-R) [36],
Spanish validation [37]: the IES-R is a 22-item
self-report measure that assesses subjective distress
caused by traumatic events. Items correspond
directly to 14 of the 17 DSM-IV symptoms of PTSD.
Patients are asked to identify a specific stressful life
event and then indicate how much they were
distressed or bothered during the past 7 days. Items
are rated on a 5-point scale ranging from 0 = not at
all, 1 = a little bit, 2 = moderately, 3 = quite a bit and
4 = extremely. The IES-R yields a total score (ranging
from 0 to 88) and subscale scores can also be calcu-
lated for the Intrusion, Avoidance and Hyperarousal
subscales
3. The Holmes-Rahe Life Stress Inventory [38], Spanish
validation [39]. This scale assesses frequency of 43
common stressful life events that occurred over the
previous 12 months, providing a standardized
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measure of the impact of these stressors [40]. Inter-
pretation of the overall score is difficult because of
the large differences in each person’s ability to cope
and their particular reactions to stress, but there are
some general guidelines. Scores below 150 reflect
low levels of stress, scores between 150 and 299
represent a 50% risk of illness in the near future and
scores above 300 represent an 80% risk of developing
a stress-related illness [38]
Cognitive profiles and overall functioning will be
evaluated using (see Table 3):
1. Screen for Cognitive Impairment in Psychiatry
(SCIP) [41], Spanish validation [42]: the SCIP is a
short tool to assess cognitive impairment in
psychiatric patients and consists of five subtests that
assess immediate and delayed verbal learning,
working memory, verbal language, and processing
speed. Three alternate forms facilitate their
application to assess possible cognitive changes and
avoid habituation and learning effects in repetitive
within-patient evaluations. The SCIP-S yields a total
score and subscale scores can also be calculated for
every single cognitive function evaluated
2. The Mayer-Salovey-Caruso Emotional Intelligence
Test (MSCEIT) [43], Spanish validation [44]. The
MSCEIT evaluates emotional intelligence based on
scenarios typical of everyday life. This test measures
how well people perform tasks and solve emotional
problems, rather than having them provide their
own subjective assessment of their emotional skills
[43]. The MSCEIT consists of 141 items and the
results are presented in a comprehensive personal
summary report providing graphical representations
of 15 separate emotional intelligence scores and a
detailed explanation of score meanings. The MSCEIT
provides a total score, two general areas of emotional
intelligence (experiential and strategic), four branches
of emotional intelligence (perceiving emotions, using
emotions, understanding emotions and managing
emotions) and eight specific emotional intelligence
tasks (identifying emotions in pictures and in faces,
relating emotions to sensation and to thinking,
analyzing complex emotions and chains of emotions,
and incorporating into decision-making your own
emotions and the emotions of others)
3. Functioning Assessment Short Test (FAST) [45]: the
FAST is a brief instrument to evaluate performance
in six different areas of functioning, such as
autonomy, occupational functioning, cognitive
functioning, finances, relationships and leisure.
This test contains 24 items and all of them are rated
on a 4-point scale. The global score is obtained by
summing the scores of each item (ranging from 0 to
72); higher scores indicate poorer functional status
Finally, to measure patient satisfaction with the treat-
ment, we will use the Client Satisfaction Questionnaire
(CSQ-8) [46], Spanish validation [47]. The CSQ-8 is an
eight-item, easily scored and administered measurement
that is designed to measure client satisfaction with ser-
vices. The items for the CSQ-8 were selected on the
basis of ratings by mental health professionals of a num-
ber of items that could be related to client satisfaction
and by subsequent factor analysis. The CSQ-8 is unidi-
mensional, yielding a homogeneous estimate of general
satisfaction with services. The CSQ-8 provides a total
Table 1 Measurements to evaluate clinical variables
Clinical
variable
Measurement interview/
Self-report
T0 T1 T2 T3 T4 T5
Baseline Mid-treatment Post treatment FU 12 months FU 24 months
Mania Young x x x X x x
Depression BDRS x x x X x x
Severity CGI-BP-M x x x X x x
FU Follow-up, YMRS Young Mania Rating Scale, BDRS Bipolar Depression Rating Scale, CGI-BP-M Clinical Global Impression Scale modified for bipolar disorder
Table 2 Measurements to evaluate trauma symptoms
Clinical
variable
Measurement interview/
Self-report
T0 T1 T2 T3 T4 T5
Baseline Mid-treatment Post treatment FU 12 months FU 24 months
PTSD CAPS x x x x
Adverse events IES-R x x x x
H-RLSI x
SUD x x x x
FU Follow-up, PTSD Posttraumatic Stress Disorder, CAPS The Clinician-administered PTSD Scale, IES-R Impact Event Scale, H-RLSI The Holmes-Rahe Life Stress
Inventory, SUD Subjective Units of Distress
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score (ranging from 8 to 32), with high scores indicating
greater satisfaction.
Statistical analysis
The baseline distribution of sociodemographic and
clinical characteristics in each treatment arm will be
reported using descriptive statistics.
The main hypothesis of the change in the time to relapse
(in weeks) will be analyzed using Cox regressions, and the
hypotheses of the changes in the scores of clinical scales as
compared to baseline will be tested using repeated measures
analyses of variance (ANOVAs) that will include time, treat-
ment arm and their interaction. Those variables that show
statistically significant between-arm differences at baseline
will be added as covariates in the Cox regressions and re-
peated measures ANOVAs. For each of the analyses effect
size measures (hazard ratio or Hedges’ g) will be estimated.
An intention-to-treat (ITT) analysis will be employed
to provide unbiased comparisons among the treatment
groups, using multiple imputations to deal with the
losses of follow-up.
R software will be used to carry out the statistical analyses.
Discussion
This trial is based on our first preliminary RCT of EMDR in
traumatized bipolar patients, with positive results in affective
and trauma-related symptoms in the EMDR group when
compared to treatment as usual [24]. The main goal of the
current study is to test in a large multicenter sample of bipo-
lar I and II patients, if a newly developed, specific EMDR
protocol for BD [25], compared to ST, can reduce affective
relapses, improve affective and trauma-related symptoms and
result in a better performance of cognition and functioning.
We believe that this trial is an important contribution in the
treatment of bipolar patients because it aims to improve the
course and prognosis of the disorder and, therefore, their
quality of life and overall functionality. As one of the increas-
ingly used psychotherapeutic tools [21], we want to explore
whether or not EMDR may represent a potentially relevant
therapeutic strategy for bipolar I and II patients with trau-
matic events in their history. Together with the work on
trauma-related symptoms, we will target four specific risk fac-
tors for relapses such as lack of insight, bad adherence,
insufficient awareness of prodromal symptoms and de-
idealisation of manic symptoms. The fifth subprotocol
consists of an EMDR intervention directed towards mood
stabilization via bilateral stimulation. But why do we believe
that EMDR might have a mood-stabilizing effect on bipolar
patients? This idea is based on a recent study which sug-
gested that EMDR might modulate the Default Mode Net-
work (DMN) in traumatized bipolar patients [48]. First
identified in 2001, the DMN is an interconnected series of
brain regions, including prominently the medial frontal cor-
tex and also the posterior cingulate cortex/precuneus, which
are highly active at rest but deactivate during the perform-
ance of attention-demanding tasks [49, 50]. DMN dysfunc-
tion is currently implicated in major psychiatric disorders,
such in BD across all phases of the disorder [51]. Interest-
ingly, another study has also found alterations in the DMN in
PTSD [52]. In our study [48] we found marked improvement
after receiving EMDR for subsyndromal mood symptoms.
Surprisingly, the patient also showed changes on functional
magnetic resonance imaging (MRI) in the direction of
normalization of the DMN. This suggests that some of the
persisting neurofunctional changes which have been found to
characterize BD may not in fact be immutable but can
change alongside with changes in clinical status. This prelim-
inary result needs replication but provides a possible neuro-
biological rational behind the mechanism of action of EMDR.
To understand better the relationship between the
presence of traumatic events and BD, we will study sev-
eral variables before, during and after treatment. We will
assess clinical severity, cognitive and overall functioning
variables with specific and validated instruments.
This study aims to replicate the positive results of our
pilot study in a larger sample of BD patients, thus strength-
ening the role of EMDR as a therapy and providing a fast
and safe additional tool to established psychosocial inter-
ventions that are currently available in the treatment of BD.
Strengths of this trial include an innovative, relatively new
psychotherapeutic tool (which fills a striking lack of data in
the field), a solid methodology and a large observational
period of 2 years. The results of this trial are expected to
spawn several publications in high-impact factor journals
and, if the treatment is useful, will be integrated in future
clinical treatment guidelines for BD.
Table 3 Measurements to evaluate cognitive and functional profiles and satisfaction with the treatment
Clinical
variable
Measurement interview/
Self-report
T0 T1 T2 T3 T4 T5
Baseline Mid-treatment Post treatment FU 12 months FU 24 months
Cognition SCIP x x x x
MSCEIT x x x x
Functionality FAST x x x x
Satisfaction CLQ-8 x
FU Follow-up, SCIP Screen for Cognitive Impairment in Psychiatry, MSCEIT The Mayer-Salovey-Caruso Emotional Intelligence Test, FAST Functioning Assessment
Short Test, CLQ-8 Client Satisfaction Questionnaire
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Limitations
Differences in pharmacological treatment received by
patients could be a possible source of clinical noise. To
partly overcome this limitation, the “pharmacological
treatment” variable will be taken into account in the statis-
tical analysis. Moreover, it should be noted that all partici-
pating centers have extensive experience in the treatment
of BD and use standardized treatment protocols, which
would also contribute to limit this potential issue.
Trial status
Intervention and assessment training was performed in
June 2016 and patient recruitment began in July 2016.
Additional files
Additional file 1: SPIRIT flow diagram. (PDF 83 kb)
Additional file 2: SPIRIT Checklist. (DOC 122 kb)
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